Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140006 | 0.92 | IL4I1 (0.36) | METAP1TDP2MAOAMAOBSLC5A2 | |
| SCHEMBL20139413 | 0.83 | METAP1 (0.38) | METAP1TDP2MAOAMAOBSLC5A2 | |
| SCHEMBL20140286 | 0.83 | METAP1 (0.38) | METAP1TDP2MAOAMAOBSLC5A2 | |
| SCHEMBL20139367 | 0.81 | SLC5A2 (0.48) | SLC5A2SLC5A1CCR5 | |
| SCHEMBL20139995 | 0.80 | KDM4E (0.45) | — | |
| SCHEMBL20140092 | 0.78 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL20139399 | 0.76 | SLC5A2 (0.42) | SLC5A2SLC5A1CCR5 | |
| SCHEMBL20139674 | 0.75 | IL4I1 (0.36) | METAP1TDP2MAOAMAOBSLC5A2 | |
| SCHEMBL20139694 | 0.75 | IL4I1 (0.36) | METAP1TDP2SLC5A2SLC5A1CMA1 | |
| SCHEMBL14488028 | 0.75 | METAP1 (0.60) | METAP1TDP2PARP11CMA1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | METAP1 2835/4885TDP2 2943/4885MAOA 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.